Physician profile
Robert Orgain Hardy
NPI 1982791729
$2,196.60
in general payments reported to CMS, 2019-2025
13 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $325 · 2021: $391 · 2022: $308 · 2023: $397 · 2024: $314 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $713.99 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $340.92 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $338.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $157.88 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $129.34 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $102.68 | 2019-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $91.79 | 2021-2025 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $81.51 | 2021-2025 | Hetlioz, Fanapt |
| Allergan, INC. | $76.65 | 2019-2020 | |
| Axsome Therapeutics, INC. | $53.94 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $39.19 | 2025 | Austedo Xr, Uzedy |
| Indivior INC. | $38.50 | 2022-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.92 | 2023-2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.